These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3026150)

  • 1. Type III hyperlipoproteinemia: a focus on lipoprotein receptor-apolipoprotein E2 interactions.
    Innerarity TL; Hui DY; Bersot TP; Mahley RW
    Adv Exp Med Biol; 1986; 201():273-88. PubMed ID: 3026150
    [No Abstract]   [Full Text] [Related]  

  • 2. Defective hepatic lipoprotein receptor binding of beta-very low density lipoproteins from type III hyperlipoproteinemic patients. Importance of apolipoprotein E.
    Hui DY; Innerarity TL; Mahley RW
    J Biol Chem; 1984 Jan; 259(2):860-9. PubMed ID: 6319389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoproteins of special significance in atherosclerosis. Insights provided by studies of type III hyperlipoproteinemia.
    Mahley RW; Innerarity TL; Rall SC; Weisgraber KH
    Ann N Y Acad Sci; 1985; 454():209-21. PubMed ID: 3000263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein E (role in lipoprotein metabolism and pathophysiology of hyperlipoproteinemia type III).
    Utermann G
    Ric Clin Lab; 1982; 12(1):23-30. PubMed ID: 6283616
    [No Abstract]   [Full Text] [Related]  

  • 5. Apolipoprotein E: receptor binding properties.
    Weisgraber KH; Innerarity TL; Rall SC; Mahley RW
    Adv Exp Med Biol; 1985; 183():159-71. PubMed ID: 2412412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High receptor binding affinity of lipoproteins in atypical dysbetalipoproteinemia (type III hyperlipoproteinemia).
    Chappell DA
    J Clin Invest; 1989 Dec; 84(6):1906-15. PubMed ID: 2556448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
    Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
    Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia.
    Dong LM; Parkin S; Trakhanov SD; Rupp B; Simmons T; Arnold KS; Newhouse YM; Innerarity TL; Weisgraber KH
    Nat Struct Biol; 1996 Aug; 3(8):718-22. PubMed ID: 8756331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein receptors and cholesterol homeostasis.
    Mahley RW; Innerarity TL
    Biochim Biophys Acta; 1983 May; 737(2):197-222. PubMed ID: 6303423
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification of a new structural variant of human apolipoprotein E, E2(Lys146 leads to Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype.
    Rall SC; Weisgraber KH; Innerarity TL; Bersot TP; Mahley RW; Blum CB
    J Clin Invest; 1983 Oct; 72(4):1288-97. PubMed ID: 6313758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identical structural and receptor binding defects in apolipoprotein E2 in hypo-, normo-, and hypercholesterolemic dysbetalipoproteinemia.
    Rall SC; Weisgraber KH; Innerarity TL; Mahley RW
    J Clin Invest; 1983 Apr; 71(4):1023-31. PubMed ID: 6300187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of high apolipoprotein E blood levels and HDL in development of familial dysbetalipoproteinemia in ε2ε2 subjects.
    Corsetti JP; Sparks CE; Bakker SJL; Gruppen EG; Dullaart RPF
    Clin Biochem; 2018 Feb; 52():67-72. PubMed ID: 29157655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein EBethesda: a new variant of apolipoprotein E associated with type III hyperlipoproteinemia.
    Gregg RE; Ghiselli G; Brewer HB
    J Clin Endocrinol Metab; 1983 Nov; 57(5):969-74. PubMed ID: 6578216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Familial type III hyperlipoproteinemia].
    Kataoka S; Egusa G
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():69-73. PubMed ID: 11347154
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of infusion of normal plasma on lipoproteins in type III hyperlipoproteinemia.
    Stuyt PM; Demacker PN; van 't Laar A
    Horm Metab Res; 1981 Dec; 13(12):715-6. PubMed ID: 7319472
    [No Abstract]   [Full Text] [Related]  

  • 16. Apolipoprotein E Bethesda. Isolation and partial characterization of a variant of human apolipoprotein E isolated from very low density lipoproteins.
    Ghiselli G; Gregg RE; Brewer HB
    Biochim Biophys Acta; 1984 Jul; 794(2):333-9. PubMed ID: 6428460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects.
    Rall SC; Weisgraber KH; Innerarity TL; Mahley RW
    Proc Natl Acad Sci U S A; 1982 Aug; 79(15):4696-700. PubMed ID: 6289314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of apolipoprotein E in the lipolytic conversion of beta-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia.
    Ehnholm C; Mahley RW; Chappell DA; Weisgraber KH; Ludwig E; Witztum JL
    Proc Natl Acad Sci U S A; 1984 Sep; 81(17):5566-70. PubMed ID: 6591204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type III hyperlipoproteinemia associated with apolipoprotein E deficiency.
    Ghiselli G; Schaefer EJ; Gascon P; Breser HB
    Science; 1981 Dec; 214(4526):1239-41. PubMed ID: 6795720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type III hyperlipoproteinemia with xanthomas and multiple myeloma.
    Burnside NJ; Alberta L; Robinson-Bostom L; Bostom A
    J Am Acad Dermatol; 2005 Nov; 53(5 Suppl 1):S281-4. PubMed ID: 16227109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.